Assessing Cellular and Transcriptional Diversity of Ileal Mucosa Among Treatment-Naïve and Treated Crohn's Disease.
Crohn’s disease
enterocytes
ileum
inflammatory bowel disease
single cell RNA-seq
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
received:
11
08
2022
pubmed:
8
10
2022
medline:
3
2
2023
entrez:
7
10
2022
Statut:
ppublish
Résumé
Crohn's disease is a lifelong disease characterized by chronic inflammation of the gastrointestinal tract. Defining the cellular and transcriptional composition of the mucosa at different stages of disease progression is needed for personalized therapy in Crohn's. Ileal biopsies were obtained from (1) control subjects (n = 6), (2) treatment-naïve patients (n = 7), and (3) established (n = 14) Crohn's patients along with remission (n = 3) and refractory (n = 11) treatment groups. The biopsies processed using 10x Genomics single cell 5' yielded 139 906 cells. Gene expression count matrices of all samples were analyzed by reciprocal principal component integration, followed by clustering analysis. Manual annotations of the clusters were performed using canonical gene markers. Cell type proportions, differential expression analysis, and gene ontology enrichment were carried out for each cell type. We identified 3 cellular compartments with 9 epithelial, 1 stromal, and 5 immune cell subtypes. We observed differences in the cellular composition between control, treatment-naïve, and established groups, with the significant changes in the epithelial subtypes of the treatment-naïve patients, including microfold, tuft, goblet, enterocyte,s and BEST4+ cells. Surprisingly, fewer changes in the composition of the immune compartment were observed; however, gene expression in the epithelial and immune compartment was different between Crohn's phenotypes, indicating changes in cellular activity. Our study identified cellular and transcriptional signatures associated with treatment-naïve Crohn's disease that collectively point to dysfunction of the intestinal barrier with an increase in inflammatory cellular activity. Our analysis also highlights the heterogeneity among patients within the same disease phenotype, shining a new light on personalized treatment responses and strategies.
Sections du résumé
BACKGROUND
Crohn's disease is a lifelong disease characterized by chronic inflammation of the gastrointestinal tract. Defining the cellular and transcriptional composition of the mucosa at different stages of disease progression is needed for personalized therapy in Crohn's.
METHODS
Ileal biopsies were obtained from (1) control subjects (n = 6), (2) treatment-naïve patients (n = 7), and (3) established (n = 14) Crohn's patients along with remission (n = 3) and refractory (n = 11) treatment groups. The biopsies processed using 10x Genomics single cell 5' yielded 139 906 cells. Gene expression count matrices of all samples were analyzed by reciprocal principal component integration, followed by clustering analysis. Manual annotations of the clusters were performed using canonical gene markers. Cell type proportions, differential expression analysis, and gene ontology enrichment were carried out for each cell type.
RESULTS
We identified 3 cellular compartments with 9 epithelial, 1 stromal, and 5 immune cell subtypes. We observed differences in the cellular composition between control, treatment-naïve, and established groups, with the significant changes in the epithelial subtypes of the treatment-naïve patients, including microfold, tuft, goblet, enterocyte,s and BEST4+ cells. Surprisingly, fewer changes in the composition of the immune compartment were observed; however, gene expression in the epithelial and immune compartment was different between Crohn's phenotypes, indicating changes in cellular activity.
CONCLUSIONS
Our study identified cellular and transcriptional signatures associated with treatment-naïve Crohn's disease that collectively point to dysfunction of the intestinal barrier with an increase in inflammatory cellular activity. Our analysis also highlights the heterogeneity among patients within the same disease phenotype, shining a new light on personalized treatment responses and strategies.
Identifiants
pubmed: 36206201
pii: 6752324
doi: 10.1093/ibd/izac201
pmc: PMC9890215
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-285Subventions
Organisme : NIDDK NIH HHS
ID : T32 DK108735
Pays : United States
Organisme : NIH HHS
ID : P51 OD011132
Pays : United States
Organisme : NIH HHS
ID : S10 OD026799
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):544-558
pubmed: 33712743
Inflamm Bowel Dis. 2020 Jan 6;26(2):e8-e9
pubmed: 31769481
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):205-17
pubmed: 25732745
J Exp Med. 2020 Feb 3;217(2):
pubmed: 31753849
Nat Med. 2021 May;27(5):806-814
pubmed: 33958799
Lancet. 2017 Apr 29;389(10080):1710-1718
pubmed: 28259484
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Gastroenterology. 2021 Jul;161(1):47-65
pubmed: 33940007
Cell. 2019 Sep 5;178(6):1493-1508.e20
pubmed: 31474370
J Gastroenterol. 2018 Sep;53(9):1035-1047
pubmed: 29374777
PLoS One. 2019 Oct 16;14(10):e0222952
pubmed: 31618209
Cell Mol Gastroenterol Hepatol. 2021;12(4):1267-1280
pubmed: 34271224
J Clin Immunol. 2004 Jan;24(1):74-85
pubmed: 14997037
Cell. 2018 Nov 15;175(5):1307-1320.e22
pubmed: 30392957
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
J Crohns Colitis. 2021 Oct 7;15(10):1621-1630
pubmed: 33773497
J Clin Invest. 2019 Jun 11;129(9):3670-3685
pubmed: 31184596
Gut. 2004 Dec;53(12):1817-24
pubmed: 15542521
Mucosal Immunol. 2018 Jan;11(1):120-130
pubmed: 28401939
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
J Clin Invest. 2014 Aug;124(8):3617-33
pubmed: 25003194
Gastro Hep Adv. 2022;1(3):457-460
pubmed: 35634262
Cell. 2018 Oct 4;175(2):372-386.e17
pubmed: 30270042
Blood Cells Mol Dis. 2005 Sep-Oct;35(2):122-8
pubmed: 16027013
Front Immunol. 2018 Sep 25;9:2144
pubmed: 30319613
Nature. 2019 Mar;567(7746):49-55
pubmed: 30814735
Nature. 2021 Sep;597(7875):250-255
pubmed: 34497389
Am J Pathol. 2016 May;186(5):1166-79
pubmed: 26948422
Gastroenterology. 2020 Aug;159(2):591-608.e10
pubmed: 32428507
Curr Opin Pharmacol. 2020 Dec;55:90-98
pubmed: 33166872
Dev Cell. 2020 Dec 21;55(6):771-783.e5
pubmed: 33290721
Cell. 2019 Jul 25;178(3):714-730.e22
pubmed: 31348891
Sci Rep. 2014 Dec 05;4:7343
pubmed: 25475414
Cell Mol Gastroenterol Hepatol. 2020;10(1):101-112
pubmed: 32004754
World J Gastroenterol. 2016 May 28;22(20):4794-801
pubmed: 27239106
World J Gastroenterol. 2010 Sep 14;16(34):4264-71
pubmed: 20818809
Immunity. 2019 Nov 19;51(5):885-898.e7
pubmed: 31542340
Dis Mon. 2018 Feb;64(2):20-57
pubmed: 28826742
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1269-81
pubmed: 27033518
BMC Med Genomics. 2021 Jul 29;14(1):194
pubmed: 34325702